Media headlines about Akari Therapeutics (NASDAQ:AKTX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akari Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.2736776505875 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- 684,000 Shares in Akari Therapeutics PLC (AKTX) Acquired by AWM Investment Company Inc. (americanbankingnews.com)
- Contrasting Flex Pharma (FLKS) & Akari Therapeutics (AKTX) (americanbankingnews.com)
- Zacks: Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 EPS (americanbankingnews.com)
- Akari Therapeutics PLC (AKTX) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
Several research analysts have commented on the stock. ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Zacks Investment Research raised shares of Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 price objective for the company in a report on Monday, November 13th. Finally, B. Riley assumed coverage on shares of Akari Therapeutics in a report on Thursday, February 8th. They set a “neutral” rating and a $3.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $6.38.
ILLEGAL ACTIVITY WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3254092/akari-therapeutics-aktx-getting-somewhat-favorable-news-coverage-analysis-finds.html.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.